Life after the women's health initiative: Evaluation of postmenopausal symptoms and use of alternative therapies after discontinuation of hormone therapy

Pharmacotherapy

Volumn 26, Issue 10, 2006, Pages 1403-1409

  Shrader, Sarah P ^a   Ragucci, Kelly R ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alternative therapy; Discontinuation; Hormone therapy; Menopausal symptoms; Menopause; Nonhormonal

Indexed keywords

ALENDRONIC ACID; ANGELICA SINENSIS EXTRACT; CALCIUM; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESCITALOPRAM; FLUOXETINE; HERBACEOUS AGENT; HORMONE DERIVATIVE; ISOFLAVONE DERIVATIVE; PAROXETINE; PRIMROSE OIL; RED CLOVER EXTRACT; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE; WILD YAM EXTRACT;

ADULT; ALTERNATIVE MEDICINE; ARTICLE; CANCER; CARDIOVASCULAR DISEASE; DEPRESSION; ELECTRONIC MEDICAL RECORD; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PALLIATIVE THERAPY; PATIENT EDUCATION; PHARMACIST; RETROSPECTIVE STUDY; TELEPHONE; TREATMENT INDICATION; TREATMENT OUTCOME; URINARY DYSFUNCTION; VAGINA DISEASE;

ADULT; COMPLEMENTARY THERAPIES; FEMALE; HEALTH SURVEYS; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; QUALITATIVE RESEARCH; QUALITY OF LIFE; RETROSPECTIVE STUDIES; WOMEN'S HEALTH;

EID: 33749481183     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.10.1403     Document Type: Article

References (21)

1. Wyeth Pharmaceuticals Inc. Premarin (conjugated equine estrogens) package insert. Philadelphia, PA; 2005.
2. Greeridale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the postmenopausal estrogen/progestin interventions trial. Obstet Gynecol 1998;92:982-8.
3. Barnabei VM, Grady D, Stovall DW, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol 2002;100:1209-18.
4. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized control trial. JAMA 2002;288:321-33.
5. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
6. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA 2002;288:49-57.
7. The North American Menopause Society. Estrogen and progestogen use in peri- and postmenopausal women: September 2003 position statement of the North American Menopause Society. Available from http://www.menopause.org/ positionstatement.pdf. Accessed January 1, 2006.
8. The American College of Obstetricians and Gynecologists. New recommendations based on ACOG's task force report on hormone therapy. Available from http://www.acog.org/from_ home/publications/press_releases/nr08-30-02.cfm. Accessed January 1, 2006.
9. U.S. Food and Drug Administration. FDA updates hormone therapy information for postmenopausal women. Available from http://www.fda.gov/bbs/ topics/NEWS/2004/NEW01022. html. Accessed January 1, 2006.
10. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the women's health initiative. JAMA 2004;292:1983-8.
11. Bestul MB, McCollum M, Hansen LB, Saseen JJ. Impact of the women's health initiative trial results on hormone replacement therapy. Pharmacotherapy 2004;24:495-9.
12. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;4:CD002978.
13. Ockene JK, Barad DH, Cochrane BB, et al. Symptom experience after discontinuing use of estrogen plus progestin. JAMA 2005;294:183-92.
14. Schonberg MA, Wee CC. Menopausal symptom management and prevention counseling after the women's health initiative among women seen in an internal medicine practice. J Womens Health 2005;14:507-14.
15. Haskell SG. After the women's health initiative: postmenopausal women's experiences with discontinuing estrogen replacement therapy. J Womens Health 2004;13:438-42.
16. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the women's health initiative on women's decisions to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32.
17. Kronenberg F, Fugh-Berman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized controlled trials. Ann Intern Med 2002;137:805-13.
18. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003;10:465-76.
19. Sicat BL, Brokaw DK. Nonhormonal alternatives for the treatment of hot flashes. Pharmacotherapy 2004;24:79-93.
20. The North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Available from http://www.menopause.org/aboutmeno/consensus.htm. Accessed January 1, 2006.
21. Williams RS, Christie D, Sistrom C. Assessment of the understanding of the risks and benefits of hormone replacement therapy (HRT) in primary care physicians. Am J Obstet Gynecol 2005;193:551-6.